Century Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IPSC | ALLO | FATE | CABA | SANA | AGEN | |
|---|---|---|---|---|---|---|
| Market cap | 302.40M | 411.13M | 250.42M | 240.75M | 766.36M | 314.78M |
| P/E (TTM) | — | — | — | — | — | 2.8 |
| Forward P/E | -3.7 | -1.9 | -2.2 | -1.2 | -4.6 | -63.4 |
| Price/book | 1.3 | 0.9 | 1.6 | 1.1 | 5.0 | -1.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +209.26% | +13.33% | +100.96% | −42.74% | −36.79% | +81.51% |
| Today | +9.87% | +6.25% | +2.45% | 0.00% | +4.92% | +4.50% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IPSC news ›Century Therapeutics (NASDAQ:IPSC) Stock Rating Lowered by Wall Street Zen
Posted by Tristan Rich on Nov 2nd, 2026 Century Therapeutics (NASDAQ:IPSC – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday,…
More from 1 other outlet
Fate Therapeutics, Inc. Announces Appointment of Jamie Harrell as Senior Vice President, Market Development & Commercial Operations, Effective October 12, 2026
Fate Therapeutics, Inc. appointed Jamie Harrell as Senior Vice President, Market Development & Commercial Operations, effective October 12, 2026. Mr. Harrell brings more than 25 years of commercial... appointed Jamie Harrell as Senior Vice…
Century Therapeutics Seeks Investor Meetings at London Conference
PHILADELPHIA, PA — Century Therapeutics Inc. (Nasdaq: IPSC) will meet with investors at the Jefferies Global Healthcare Conference in London on November 18, as the Philadelphia biotechnology company advances experimental stem cell-derived…
Denali Therapeutics (NASDAQ:DNLI) vs. Century Therapeutics (NASDAQ:IPSC) Head-To-Head Contrast
Posted by Mitch Edgeman on Oct 19th, 2026 Denali Therapeutics (NASDAQ:DNLI – Get Free Report) and Century Therapeutics (NASDAQ:IPSC – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the…
Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
Investing News Network Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (IPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimm
ISSCR 2027 Opens Registration and Abstracts for Hallmark Meeting in San Francisco (IMAGE)
ISSCR 2027 Opens Registration and Abstracts for Hallmark Meeting in San Francisco [IMAGE] EurekAlert! Scientific exchange, groundbreaking advances in stem cell biology, emerging clinical data, and cutting-edge AI technologies will take…
Coya Therapeutics expects FTD trial to start in 2027
The planned Phase 2 trial of COYA 302 for frontotemporal dementia is now expected in 2027, as resources are prioritized for ALS development. Coya is prioritizing resources toward ongoing ALS development and timely ALSTARS milestones. Its…
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
AUSTIN, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company... 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc (NASDAQ: FLNA, "Filana…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com3
- globenewswire.com2
- defenseworld.net1
- investingnews.com1
- manilatimes.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.